**Publication list of studies using NCRAS data since 2013**

**Use and Outcomes of Treatments**

* Aggarwal A, Lewis D, Charman SC, et al. Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition. *European urology* 2017.
* Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. *European Journal of Cancer* 2014; **50**: 2838-45.
* Assayag J, Pollak MN, Azoulay L. The use of aspirin and the risk of mortality in patients with prostate cancer. *The Journal of urology* 2015; **193**: 1220-5.
* Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. The use of metformin in patients with prostate cancer and the risk of death. *Cancer Epidemiology and Prevention Biomarkers* 2014.
* Bouras G, Burns EM, Howell A-M, Bottle A, Athanasiou T, Darzi A. Risk of post-discharge venous thromboembolism and associated mortality in general surgery: a population-based cohort study using linked hospital and primary care data in England. *PLoS One* 2015; **10**: e0145759.
* Bouras G, Markar SR, Burns EM, et al. Linked Hospital and Primary Care Database Analysis of the Incidence and Impact of Psychiatric Morbidity Following Gastrointestinal Cancer Surgery in England. *Ann Surg* 2016; **264**: 93-9.
* Butler J, Gildea C, Poole J, Meechan D, Nordin A. Specialist surgery for ovarian cancer in England. *Gynecologic oncology* 2015; **138**: 700-6.
* Chamberlain C, Collin SM, Hounsome L, Owen-Smith A, Donovan JL, Hollingworth W. Equity of access to treatment on the Cancer Drugs Fund: A missed opportunity for cancer research? *Journal of Cancer Policy* 2015; **5**: 25-30.
* Coupland VH, Konfortion J, Jack RH, et al. Resection rate, hospital procedure volume and survival in pancreatic cancer patients in England: Population-based study, 2005-2009. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology* 2016; **42**: 190-6.
* Coupland VH, Lagergren J, Luchtenborg M, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008. *Gut* 2013; **62**: 961-6.
* Dajani K, Greenberg D, Patel K, et al. Significant decrease in incidence of colorectal liver metastases and increasing resectability: The impact on liver resection services. *HPB* 2016; **18**: e173.
* Dikken JL, van Sandick JW, Allum WH, et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. *The British journal of surgery* 2013; **100**: 83-94.
* Douglas-Moore JL, Hounsome L, Verne J, Kockelbergh R. Outcomes in urological cancer are strongly influenced by route to diagnosis. *Journal of Clinical Urology* 2017; **10**: 9-13.
* Downing A, Aravani A, Macleod U, et al. Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis. *Br J Cancer* 2013; **108**: 681-5.
* Downing A, Morris EJ, Aravani A, et al. The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2015; **27**: 708-12.
* Emmett M, Gildea C, Nordin A, Hirschowitz L, Poole J. Variations in Treatment of Cervical Cancer According to Tumor Morphology-Population-Based Cohort Analysis of English National Cancer Registration Data. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2017; **27**: 138-46.
* Fischer C, Lingsma H, Hardwick R, Cromwell DA, Steyerberg E, Groene O. Risk adjustment models for short-term outcomes after surgical resection for oesophagogastric cancer. *The British journal of surgery* 2016; **103**: 105-16.
* Ganesan R, Hirschowitz L, Dawson P, et al. Neuroendocrine Carcinoma of the Cervix: Review of a Series of Cases and Correlation With Outcome. *Int J Surg Pathol* 2016; **24**: 490-6.
* Gildea C, Nordin A, Hirschowitz L, Poole J. Thirty-day postoperative mortality for endometrial carcinoma in England: a population-based study. *BJOG : an international journal of obstetrics and gynaecology* 2016; **123**: 1853-61.
* Greenberg DC, Lophatananon A, Wright KA, Muir KR, Gnanapragasam VJ. Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. *PLoS One* 2015; **10**: e0119494.
* Hounsome L, Verne J, Kockelbergh R. Variation in usage of radical prostatectomy and radical radiotherapy for men with locally advanced prostate cancer. *European Journal of Cancer Care* 2015; **24**: 21.
* Hounsome LS, Verne J, McGrath JS, Gillatt DA. Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998-2010. *European urology* 2015; **67**: 1056-62.
* Johnston TJ, Shaw GL, Lamb AD, et al. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. *European urology* 2017; **71**: 381-8.
* Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? *British journal of cancer* 2016; **115**: 607.
* Luchtenborg M, Riaz SP, Coupland VH, et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. *J Clin Oncol* 2013; **31**: 3141-6.
* Luchtenborg M, Riaz SP, Lim E, et al. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009. *Thorax* 2014; **69**: 269-73.
* Mensah EE, Hounsome L, Verne J, Kockelbergh R, Mayer E. Cardiovascular outcomes in kidney cancer patients. *Journal of Clinical Urology* 2017; **10**: 24-8.
* Moller H, Riaz SP, Holmberg L, et al. High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of re-admission and death: National cohort analysis in England. *Eur J Cancer* 2016; **64**: 32-43.
* Morris E, Finan P, Spencer K, et al. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. *Clinical Oncology* 2016; **28**: 522-31.
* Morris E, Finan P, Thomas J, et al. Using the National Radiotherapy Dataset within the National Cancer Data Repository to investigate patterns of use of radiotherapy in the management of surgically treated rectal cancer across the English NHS. *European Journal of Cancer Care* 2015; **24**: 20-1.
* Pal S, Luchtenborg M, Davies EA, Jack RH. The treatment and survival of patients with triple negative breast cancer in a London population. *SpringerPlus* 2014; **3**: 553.
* Pathak R, Wallington M, Saunders C, et al. Rapid analysis of outcomes using the Systemic Anti-Cancer Therapy (SACT) dataset. *Clinical Oncology* 2017.
* Redaniel MT, Martin RM, Blazeby JM, Wade J, Jeffreys M. The association of time between diagnosis and major resection with poorer colorectal cancer survival: a retrospective cohort study. *BMC cancer* 2014; **14**: 642.
* Redaniel MT, Martin RM, Cawthorn S, Wade J, Jeffreys M. The association of waiting times from diagnosis to surgery with survival in women with localised breast cancer in England. *Br J Cancer* 2013; **109**: 42-9.
* Redaniel MT, Martin RM, Gillatt D, Wade J, Jeffreys M. Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. *BMC Cancer* 2013; **13**: 559.
* Round CE, Williams MV, Mee T, et al. Radiotherapy demand and activity in England 2006-2020. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2013; **25**: 522-30.
* Spencer K, Morris E, Dugdale E, et al. 30 day mortality in adult palliative radiotherapy--A retrospective population based study of 14,972 treatment episodes. *Radiother Oncol* 2015; **115**: 264-71.
* Taylor EF, Thomas JD, Whitehouse LE, et al. Population-based study of laparoscopic colorectal cancer surgery 2006-2008. *The British journal of surgery* 2013; **100**: 553-60.
* Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer–a cohort study using linked United Kingdom databases. *European journal of cancer* 2013; **49**: 1404-13.
* Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. *Blood* 2016; **127**: 849-57.
* Wallington M, Saxon EB, Bomb M, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. *Lancet Oncol* 2016; **17**: 1203-16.
* Warwick J, Will O, Allgood P, Miller R, Duffy S, Greenberg D. Variation in colorectal cancer treatment and survival: a cohort study covering the East Anglia region. *Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland* 2013; **15**: 1243-52.
* Williams M, Treasure P, Greenberg D, Brodbelt A, Collins P. Surgeon volume and 30 day mortality for brain tumours in England. *Br J Cancer* 2016; **115**: 1379-82.
* Nossiter J, Sujenthiran A, Charman SC, et al. Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. *Br J Cancer* 2018; **118**: 489-94.
* Pathak R, Wallington M, Saunders C, et al. Rapid analysis of outcomes using the Systemic Anti-Cancer Therapy (SACT) dataset. *Clinical Oncology* 2017; **29**: e134-e6.
* Sujenthiran A, Nossiter J, Charman SC, et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2017; **99**: 1253-60.
* Sujenthiran A, Nossiter J, Parry M, et al. National cohort study comparing severe medium-term urinary complications after robot-assisted vs laparoscopic vs retropubic open radical prostatectomy. *BJU international* 2018; **121**: 445-52.

**Treatment associated survival times**

* Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. *International journal of cancer* 2013; **132**: 2404-12.
* Ball KS, Hounsome L, Verne J, Kockelbergh R. Non-transitional cell carcinoma only partly explains adverse survival outcomes in females with T1–T4 bladder cancer: A summary of UK epidemiological data. *Journal of Clinical Urology* 2017; **10**: 14-8.
* Barclay M, Gildea C, Poole J, Hirschowitz L, Menon U, Nordin A. Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2016; **26**: 56-65.
* Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK Clinical Practice Research Datalink cohort. *International journal of epidemiology* 2013; **42**: 1852-61.
* Cardwell CR, Flahavan EM, Hughes CM, et al. Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. *Cancer Causes & Control* 2014; **25**: 33-43.
* Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Moller H. Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry. *BJU international* 2013; **112**: 182-9.
* Davies E, Mak V, Ferguson J, Conaty S, Moller H. Using funnel plots to explore variation in cancer mortality across primary care trusts in South-East England. *J Public Health (Oxf)* 2008; **30**: 305-12.
* Downing A, Twelves C, Forman D, Lawrence G, Gilthorpe MS. Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. *The breast journal* 2014; **20**: 29-36.
* Dregan A, Moller H, Charlton J, Gulliford MC. Are alarm symptoms predictive of cancer survival?: population-based cohort study. *Br J Gen Pract* 2013; **63**: e807-12.
* Drugan C, Leary S, Mellor T, et al. Head and neck cancer in the south west of England, Hampshire, and the Isle of Wight: trends in survival 1996-2008. *Br J Oral Maxillofac Surg* 2013; **51**: 19-24.
* Eylert MF, Hounsome L, Verne J, Bahl A, Jefferies ER, Persad RA. Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985–2010. *BJU international* 2013; **112**.
* Kanani R, Davies EA, Hanchett N, Jack RH. The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East England. *Psychooncology* 2016; **25**: 19-27.
* Karasneh RA, Murray LJ, Hughes CM, Cardwell CR. Digoxin use after diagnosis of colorectal cancer and survival: A population-based cohort study. *Cancer Epidemiology and Prevention Biomarkers* 2015.
* Maringe C, Li R, Mangtani P, Coleman M, Rachet B. Cancer survival differences between South Asians and non-South Asians of England in 1986–2004, accounting for age at diagnosis and deprivation. *British journal of cancer* 2015; **113**: 173.
* Marshall DC, Webb TE, Hall RA, Salciccioli JD, Ali R, Maruthappu M. Trends in UK regional cancer mortality 1991-2007. *Br J Cancer* 2016; **114**: 340-7.
* Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Metformin use and survival from lung cancer: A population-based cohort study. *Lung cancer (Amsterdam, Netherlands)* 2016; **94**: 35-9.
* Mc Menamin ÚC, Murray LJ, Hughes CM, Cardwell CR. Metformin use and survival after colorectal cancer: A population‐based cohort study. *International journal of cancer* 2016; **138**: 369-79.
* McCourt C, Coleman HG, Murray LJ, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. *Br J Dermatol* 2014; **170**: 930-8.
* Moller H, Henson K, Luchtenborg M, et al. Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England. *Br J Cancer* 2016; **115**: 1408-15.
* Morris E, Penegar S, Whitehouse L, et al. A retrospective observational study of the relationship between family history and survival from colorectal cancer. *British journal of cancer* 2013; **108**: 1502.
* Morris M, Woods L, Bhaskaran K, Rachet B. Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening programme and Clinical Practice Research Datalink. *BMC cancer* 2017; **17**: 155.
* Niksic M, Rachet B, Duffy SW, Quaresma M, Møller H, Forbes LJ. Is cancer survival associated with cancer symptom awareness and barriers to seeking medical help in England? An ecological study. *British journal of cancer* 2016; **115**: 876.
* O'Hara C, Moran A, Whelan JS, et al. Trends in survival for teenagers and young adults with cancer in the UK 1992-2006. *Eur J Cancer* 2015; **51**: 2039-48.
* Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. *The Lancet* 2015; **385**: 1206-18.
* Redaniel MT, Pulte D, Jeffreys M. Survival disparities by age and country of diagnosis for patients with acute leukemia. *Leuk Lymphoma* 2015; **56**: 2787-92.
* Sartipy U. Better survival after lung cancer surgery in high-volume hospitals. *Thorax* 2013: thoraxjnl-2013-204661.
* Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. *Br J Haematol* 2013; **162**: 509-16.
* Stark D, Bowen D, Dunwoodie E, et al. Survival patterns in teenagers and young adults with cancer in the United Kingdom: Comparisons with younger and older age groups. *Eur J Cancer* 2015; **51**: 2643-54.
* Emmett M, Gildea C, Nordin A, Hirschowitz L, Poole J. Cervical cancer - does the morphological subtype affect survival rates? *J Obstet Gynaecol* 2018: 1-8.

**Follow-up of clinical trials**

* Appleyard SE, Gilbert DC. Innovative Solutions for Clinical Trial Follow-up: Adding Value from Nationally Held UK Data. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2017; **29**: 789-95.
* Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. *Lancet* 2017; **389**: 1299-311.
* Hough R, Sandhu S, Khan M, et al. Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England. *BMJ Open* 2017; **7**: e017052.
* Kilburn LS, Aresu M, Banerji J, Barrett-Lee P, Ellis P, Bliss JM. Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. *Trials* 2017; **18**: 561.

**Hospital capacity, usage and end of life care**

* Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. *Int J Urol* 2015; **22**: 181-6.
* Coupland VH, Lee W, Madden P, et al. Is it possible to determine use of hospice palliative care services by matching hospice and cancer registry data? *Palliative medicine* 2010; **24**: 807-11.
* Downing A, Morris EJ, Corrigan N, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. *Gut* 2017; **66**: 89-96.
* Gillatt D, Hounsome L, Verne J. End of life care for prostate cancer. *BJU international* 2013; **112**: 24.
* Hounsome L, Verne J, Woodhams S. End of life care for urological cancer patients. *Journal of Clinical Urology* 2017; **10**: 47-51.
* Jena R, Mee T, Kirkby N, Williams M. Quantifying uncertainty in radiotherapy demand at the local and national level using the Malthus model. *Clinical Oncology* 2015; **27**: 92-8.
* Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. *Br J Cancer* 2016; **114**: 1286-92.
* Price SJ, Guilfoyle M, S JJ, et al. Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service. *BMJ Qual Improv Rep* 2013; **2**: u201857. w981.
* Tuff-Lacey A, Shaw E, Cummings R, Walker I, Johnson PW. A collaborative approach to enabling stratified cancer medicine in the UK. *Drug Discov Today* 2015; **20**: 1414-8.
* Aggarwal A, Lewis D, Mason M, Purushotham A, Sullivan R, van der Meulen J. Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study. *The lancet oncology* 2017; **18**: 1445-53.
* Aggarwal A, Lewis D, Sujenthiran A, et al. Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study. *Int J Radiat Oncol Biol Phys* 2017; **99**: 1261-70.
* McConnell H, White R, Maher J. Categorising cancers to enable tailored care planning through a secondary analysis of cancer registration data in the UK. *BMJ open* 2017; **7**: e016797.
* Walsh B, Laudicella M. Disparities In Cancer Care And Costs At The End Of Life: Evidence From England’s National Health Service. *Health Affairs* 2017; **36**: 1218-26.

**Audit of services**

* Aggarwal A, Cathcart P, Payne H, et al. The National Prostate Cancer Audit - introducing a new generation of cancer audit. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2014; **26**: 90-3.
* Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients--analysis based on the National Lung Cancer Audit. *Lung cancer (Amsterdam, Netherlands)* 2014; **83**: 396-400.
* Khakwani A, Rich AL, Powell HA, et al. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit. *Br J Cancer* 2013; **109**: 2058-65.
* Koo MM, von Wagner C, Abel GA, McPhail S, Rubin GP, Lyratzopoulos G. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. *Cancer epidemiology* 2017; **48**: 140-6.
* Hounsome L, Verne J, Persad R, et al. An audit of urological MDT decision making in the South West of England. *Journal of Clinical Urology* 2018: 2051415818755626.

**Quality of life and patient experience**

* Ashley L, Jones H, Thomas J, et al. Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system. *J Med Internet Res* 2013; **15**: e230.
* Downing A, Morris EJ, Richards M, et al. Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis. *J Clin Oncol* 2015; **33**: 616-24.
* Fisher A, Beeken RJ, Heinrich M, Williams K, Wardle J. Health behaviours and fear of cancer recurrence in 10 969 colorectal cancer (CRC) patients. *Psychooncology* 2016; **25**: 1434-40.
* Fisher A, Williams K, Beeken R, Wardle J. Recall of physical activity advice was associated with higher levels of physical activity in colorectal cancer patients. *BMJ open* 2015; **5**: e006853.
* Flott K, Hounsome L, Vuik S, Darzi A, Mayer E. A patient-centric approach to improving experience in urological cancer care. *Journal of Clinical Urology* 2017; **10**: 39-46.
* Glaser AW, Fraser LK, Corner J, et al. Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. *BMJ Open* 2013; **3**: e002317.
* Wright P, Downing A, Morris EJ, et al. Identifying Social Distress: A Cross-Sectional Survey of Social Outcomes 12 to 36 Months After Colorectal Cancer Diagnosis. *J Clin Oncol* 2015; **33**: 3423-30.

**Earlier diagnosis of cancer**

* Abel GA, Mendonca SC, McPhail S, Zhou Y, Elliss-Brookes L, Lyratzopoulos G. Emergency diagnosis of cancer and previous general practice consultations: insights from linked patient survey data. *Br J Gen Pract* 2017; **67**: e377-e87.
* Abel GA, Shelton J, Johnson S, Elliss-Brookes L, Lyratzopoulos G. Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. *Br J Cancer* 2015; **112 Suppl 1**: S129-36.
* Anastasiadis E, van der Meulen J, Emberton M. Incidental prostate cancer diagnosed following a transurethral resection of the prostate: A national database analysis in England. *Journal of Clinical Urology* 2016; **9**: 170-6.
* Chu TP, Shah A, Walker D, Coleman MP. Pattern of symptoms and signs of primary intracranial tumours in children and young adults: a record linkage study. *Arch Dis Child* 2015; **100**: 1115-22.
* Chu TP, Shah A, Walker D, Coleman MP. Where are the opportunities for an earlier diagnosis of primary intracranial tumours in children and young adults? *Eur J Paediatr Neurol* 2017; **21**: 388-95.
* Crawford SM, Skinner J, Coombes E, Jones AP. Cancer of Unknown Primary: a Cancer Registry Study of Factors Affecting Access to Diagnosis. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2017; **29**: e39-e46.
* Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets. *Br J Cancer* 2012; **107**: 1220-6.
* Forrest LF, Adams J, White M, Rubin G. Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study. *Br J Cancer* 2014; **111**: 1843-51.
* Greenberg DC, Wright KA, Lophathanon A, Muir KR, Gnanapragasam VJ. Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England. *Br J Cancer* 2013; **109**: 2115-20.
* Maclean R, Jeffreys M, Ives A, Jones T, Verne J, Ben-Shlomo Y. Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information. *BMC cancer* 2015; **15**: 500.
* McPhail S, Elliss-Brookes L, Shelton J, et al. Emergency presentation of cancer and short-term mortality. *Br J Cancer* 2013; **109**: 2027-34.
* McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. *Br J Cancer* 2015; **112 Suppl 1**: S108-15.
* Moller H, Gildea C, Meechan D, Rubin G, Round T, Vedsted P. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. *BMJ (Clinical research ed)* 2015; **351**: h5102.
* Palser TR, Cromwell DA, Hardwick RH, et al. Impact of route to diagnosis on treatment intent and 1-year survival in patients diagnosed with oesophagogastric cancer in England: a prospective cohort study. *BMJ Open* 2013; **3**: e002129.
* Rogers S, Gildea C, Meechan D, Baker R. Access, continuity of care and consultation quality: which best predicts urgent cancer referrals from general practice? *Journal of Public Health* 2014; **36**: 658-66.
* Tataru D, Jack RH, Lind MJ, Moller H, Luchtenborg M. The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006-2008. *Cancer epidemiology* 2015; **39**: 612-6.
* Herbert A, Lyratzopoulos G, Whelan J, et al. Diagnostic timeliness in adolescents and young adults with cancer: a cross-sectional analysis of the BRIGHTLIGHT cohort. *Lancet Child Adolesc Health* 2018; **2**: 180-90.
* Koo MM, von Wagner C, Abel GA, et al. The nature and frequency of abdominal symptoms in cancer patients and their associations with time to help-seeking: evidence from a national audit of cancer diagnosis. *Journal of Public Health* 2018.
* Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. *Br J Gen Pract* 2018; **68**: e63-e72.
* Zhou Y, Mendonca S, Abel G, et al. Variation in ‘fast-track’referrals for suspected cancer by patient characteristic and cancer diagnosis: evidence from 670 000 patients with cancers of 35 different sites. *British journal of cancer* 2018; **118**: 24.

**Screening studies**

* Gentry-Maharaj A, Fourkala E, Burnell M, et al. Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. *British journal of cancer* 2013; **109**: 2875.
* Hwang MJ, Evans T, Lawrence G, Karandikar S. Impact of bowel cancer screening on the management of colorectal cancer. *Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland* 2014; **16**: 450-8.
* Johns LE, Coleman DA, Swerdlow AJ, Moss SM. Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. *Br J Cancer* 2017; **116**: 246-52.
* Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW. Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On. *Cancer Epidemiol Biomarkers Prev* 2016; **25**: 455-62.
* Morris M, Woods L, Rogers N, O'sullivan E, Kearins O, Rachet B. Ethnicity, deprivation and screening: survival from breast cancer among screening-eligible women in the West Midlands diagnosed from 1989 to 2011. *British journal of cancer* 2015; **113**: 548.
* Morris M, Woods LM, Rachet B. What might explain deprivation-specific differences in the excess hazard of breast cancer death amongst screen-detected women? Analysis of patients diagnosed in the West Midlands region of England from 1989 to 2011. *Oncotarget* 2016; **7**: 49939.
* Rafia R, Brennan A, Madan J, et al. Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. *Value Health* 2016; **19**: 404-12.
* Woods L, Morris M, Rachet B. No ‘cure’within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011. *Annals of oncology* 2016: mdw408.
* Cooper JA, Parsons N, Stinton C, et al. Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model. *British journal of cancer* 2018; **118**: 285.

**Risk factors, genetics and exposure studies**

* Azoulay L, Eberg M, Benayoun S, Pollak M. 5α-Reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. *JAMA oncology* 2015; **1**: 314-20.
* Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. *Cancer Causes & Control* 2014; **25**: 329-38.
* Blows FM, Ali HR, Dawson S-J, et al. Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. *Applied Immunohistochemistry & Molecular Morphology* 2016; **24**: 221.
* Boxall N, Bennett D, Hunger M, Dolin P, Thompson PL. Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study. *BMJ Open Diabetes Res Care* 2016; **4**: e000303.
* Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. *Br J Cancer* 2015; **113**: 382-9.
* Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. *The British journal of surgery* 2014; **101**: 768-74.
* Gaitskell K, Green J, Pirie K, Reeves G, Beral V, Million Women Study C. Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. *International journal of cancer* 2016; **138**: 1076-84.
* Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC. Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. *PLoS medicine* 2016; **13**: e1002063.
* Gnanapragasam VJ, Warren AY. Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualized care without added costs. *BJU international* 2017; **119**: 366-7.
* Grimaldi-Bensouda L, Klungel O, Kurz X, et al. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). *BMJ open* 2016; **6**: e009147.
* Hicks B, Murray L, Powe D, Hughes C, Cardwell C. β-Blocker usage and colorectal cancer mortality: a nested case–control study in the UK Clinical Practice Research Datalink cohort. *Annals of oncology* 2013; **24**: 3100-6.
* Horne HN, Sherman ME, Garcia-Closas M, et al. Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. *Breast Cancer Res Treat* 2014; **143**: 181-7.
* Møller H, Purushotham A, Linklater KM, et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. *European journal of cancer* 2013; **49**: 3686-93.
* Morris EJ, Penegar S, Whiffin N, et al. A retrospective observational study of the relationship between single nucleotide polymorphisms associated with the risk of developing colorectal cancer and survival. *PloS one* 2015; **10**: e0117816.
* Pirie K, Peto R, Green J, Reeves GK, Beral V, Million Women Study C. Lung cancer in never smokers in the UK Million Women Study. *International journal of cancer* 2016; **139**: 347-54.
* Ryan NA, Evans DG, Green K, Crosbie EJ. Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. *Gynecologic oncology* 2017; **144**: 491-5.
* Theron BT, Padmanabhan H, Aladin H, et al. The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort. *United European Gastroenterol J* 2016; **4**: 754-61.
* West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population‐based cohort study. *Alimentary Pharmacology & Therapeutics* 2017; **45**: 983-90.
* Zaman S, Chapman W, Mohammed I, Gill K, Ward ST. Patients with computed tomography-proven acute diverticulitis require follow-up to exclude colorectal cancer. *Intest Res* 2017; **15**: 195-202.
* Maxwell AJ, Clements K, Hilton B, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology* 2018; **44**: 429-35.

**Incidence of cancer**

* Ayres BE, Iles M, Hounsome L, et al. Trends in incidence, mortality and treatment of penile cancer before and after centralisation of penile cancer services in England (1990–2009). *Journal of Clinical Urology* 2017; **10**: 19-23.
* Bright C, Rea D, Francis A, Feltbower R. Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013. *Cancer epidemiology* 2016; **44**: 186-94.
* Brodbelt A, Greenberg D, Winters T, et al. Glioblastoma in England: 2007-2011. *Eur J Cancer* 2015; **51**: 533-42.
* Coupland VH, Allum W, Blazeby JM, et al. Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. *BMC Cancer* 2012; **12**: 11.
* Coupland VH, Chapman P, Linklater KM, Sehgal A, Moller H, Davies EA. Trends in the epidemiology of larynx and lung cancer in south-east England, 1985-2004. *Br J Cancer* 2009; **100**: 167-9.
* Coupland VH, Kocher HM, Berry DP, et al. Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007. *Cancer epidemiology* 2012; **36**: e207-14.
* Coupland VH, Lagergren J, Konfortion J, et al. Ethnicity in relation to incidence of oesophageal and gastric cancer in England. *Br J Cancer* 2012; **107**: 1908-14.
* Coupland VH, Okello C, Davies EA, Bray F, Moller H. The future burden of cancer in London compared with England. *J Public Health (Oxf)* 2010; **32**: 83-9.
* Csikar J, Aravani A, Godson J, Day M, Wilkinson J. Incidence of oral cancer among South Asians and those of other ethnic groups by sex in West Yorkshire and England, 2001–2006. *British Journal of Oral and Maxillofacial Surgery* 2013; **51**: 25-9.
* Currin LG, Jack RH, Linklater KM, Mak V, Moller H, Davies EA. Inequalities in the incidence of cervical cancer in South East England 2001-2005: an investigation of population risk factors. *BMC Public Health* 2009; **9**: 62.
* Eylert M, Hounsome L, Persad R, et al. Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. *Journal of Clinical Urology* 2014; **7**: 90-8.
* Finlayson A, Barnes I, Sayeed S, McIver B, Beral V, Ali R. Incidence of thyroid cancer in England by ethnic group, 2001-2007. *Br J Cancer* 2014; **110**: 1322-7.
* Francis M, Dennis NL, Hirschowitz L, et al. Incidence and survival of gynecologic sarcomas in England. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2015; **25**: 850-7.
* Goon P, Greenberg D, Igali L, Levell N. Predicted cases of UK skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. *British Journal of Dermatology* 2017; **176**: 1351-3.
* Goon PK, Greenberg DC, Igali L, Levell NJ. Merkel Cell Carcinoma: rising incidence in the East of England. *J Eur Acad Dermatol Venereol* 2016; **30**: 2052-5.
* Kockelbergh R, Hounsome L, Mayer E. The Epidemiology of urological cancer 2001–2013. *Journal of Clinical Urology* 2017; **10**: 3-8.
* Konfortion J, Coupland VH, Kocher HM, Allum W, Grocock MJ, Jack RH. Time and deprivation trends in incidence of primary liver cancer subtypes in England. *Journal of evaluation in clinical practice* 2014; **20**: 498-504.
* Lai J, Elleray R, Nordin A, et al. Vulval cancer incidence, mortality and survival in England: age-related trends. *BJOG : an international journal of obstetrics and gynaecology* 2014; **121**: 728-38; discussion 39.
* Langlands F, White J, Kearins O, et al. Contralateral breast cancer: incidence according to ductal or lobular phenotype of the primary. *Clin Radiol* 2016; **71**: 159-63.
* Levell NJ, Igali L, Wright KA, Greenberg DC. Basal cell carcinoma epidemiology in the UK: the elephant in the room. *Clinical and experimental dermatology* 2013; **38**: 367-9.
* Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R. Nervous System and Intracranial Tumour Incidence by Ethnicity in England, 2001-2007: A Descriptive Epidemiological Study. *PLoS One* 2016; **11**: e0154347.
* McNally RJ, Wakeford R, James PW, et al. A geographical study of thyroid cancer incidence in north-west England following the Windscale nuclear reactor fire of 1957. *J Radiol Prot* 2016; **36**: 934-52.
* Olaleye O, Ekrikpo U, Lyne O, Wiseberg J. Incidence and survival trends of lip, intra-oral cavity and tongue base cancers in south-east England. *Ann R Coll Surg Engl* 2015; **97**: 229-34.
* Reilly GD, Muhlemann M, Lai C, et al. High incidence of skin cancer in the Channel Islands. *Clinical and experimental dermatology* 2013; **38**: 239-43.
* Saleh GM, Desai P, Collin JR, Ives A, Jones T, Hussain B. Incidence of eyelid basal cell carcinoma in England: 2000-2010. *Br J Ophthalmol* 2017; **101**: 209-12.
* Sehmer EA, Hall GJ, Greenberg DC, et al. Incidence of glioma in a northwestern region of England, 2006-2010. *Neuro Oncol* 2014; **16**: 971-4.
* Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. *Br J Cancer* 2016; **115**: 1147-55.
* Tataru D, Mak V, Simo R, Davies EA, Gallagher JE. Trends in the epidemiology of head and neck cancer in London. *Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery* 2017; **42**: 104-14.
* Walter FM, Abel GA, Lyratzopoulos G, et al. Seasonal variation in diagnosis of invasive cutaneous melanoma in Eastern England and Scotland. *Cancer epidemiology* 2015; **39**: 554-61.
* Wilkinson JR, Morris EJ, Downing A, et al. The rising incidence of anal cancer in England 1990-2010: a population-based study. *Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland* 2014; **16**: O234-9.
* Castanon A, Sasieni P. Is the recent increase in cervical cancer in women aged 20–24 years in England a cause for concern? *Preventive medicine* 2018; **107**: 21-8.
* Hicks BM, Yin H, Sinyavskaya L, Suissa S, Azoulay L, Brassard P. Metformin and the incidence of viral associated cancers in patients with type 2 diabetes. *International journal of cancer* 2017; **141**: 121-8.
* Pesola F, Ferlay J, Sasieni P. Cancer incidence in English children, adolescents and young people: past trends and projections to 2030. *Br J Cancer* 2017; **117**: 1865-73.
* Wawrzynski J, Tudge I, Fitzgerald E, et al. Report on the incidence of squamous cell carcinomas affecting the eyelids in England over a 15-year period (2000-2014). *Br J Ophthalmol* 2018: bjophthalmol-2017-310956.

**Studies of socio-demographic variation**

* Bennett VA, Davies EA, Jack RH, Mak V, Moller H. Histological subtype of lung cancer in relation to socio-economic deprivation in South East England. *BMC Cancer* 2008; **8**: 139.
* Brennan B, Stiller C, Grimer R, Dennis N, Broggio J, Francis M. Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English National Cancer Registry: 1985-2009. *Clin Sarcoma Res* 2016; **6**: 18.
* Buron Pust A, Alison R, Blanks R, et al. Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women. *International journal of cancer* 2017; **140**: 1082-90.
* Davies EA, Renshaw C, Dixon S, Moller H, Coupland VH. Socioeconomic and ethnic inequalities in screen-detected breast cancer in London. *J Public Health (Oxf)* 2013; **35**: 607-15.
* Forrest LF, White M, Rubin G, Adams J. The role of patient, tumour and system factors in socioeconomic inequalities in lung cancer treatment: population-based study. *Br J Cancer* 2014; **111**: 608-18.
* Jack RH, Davies EA, Renshaw C, et al. Differences in breast cancer hormone receptor status in ethnic groups: a London population. *Eur J Cancer* 2013; **49**: 696-702.
* Jack RH, Konfortion J, Coupland VH, et al. Primary liver cancer incidence and survival in ethnic groups in England, 2001-2007. *Cancer epidemiology* 2013; **37**: 34-8.
* Jack RH, Robson T, Davies EA. The varying influence of socioeconomic deprivation on breast cancer screening uptake in London. *J Public Health (Oxf)* 2016; **38**: 330-4.
* Li R, Daniel R, Rachet B. How much do tumor stage and treatment explain socioeconomic inequalities in breast cancer survival? Applying causal mediation analysis to population-based data. *European journal of epidemiology* 2016; **31**: 603-11.
* Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010. *BMC Med* 2015; **13**: 171.
* Nur U, Lyratzopoulos G, Rachet B, Coleman MP. The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England. *Cancer epidemiology* 2015; **39**: 641-9.
* Richards P, Ward S, Morgan J, et al. The use of surgery in the treatment of ER+ early stage breast cancer in England: Variation by time, age and patient characteristics. *European Journal of Surgical Oncology (EJSO)* 2016; **42**: 489-96.
* Rutherford M, Hinchliffe S, Abel G, Lyratzopoulos G, Lambert P, Greenberg D. How much of the deprivation gap in cancer survival can be explained by variation in stage at diagnosis: an example from breast cancer in the East of England. *International journal of cancer* 2013; **133**: 2192-200.
* Rutherford MJ, Abel G, Greenberg D, Lambert PC, Lyratzopoulos G. The impact of eliminating age inequalities in stage at diagnosis on breast cancer survival for older women. *British journal of cancer* 2015; **112**: S124-S8.
* Rutherford MJ, Ironmonger L, Ormiston-Smith N, et al. Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma. *British journal of cancer* 2015; **112**: S116.
* Samy EF, Ross J, Bolton E, Morris EJ, Oliver SE. Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008). *Leuk Lymphoma* 2015; **56**: 2660-7.
* Sayeed S, Barnes I, Ali R. Childhood cancer incidence by ethnic group in England, 2001–2007: a descriptive epidemiological study. *BMC cancer* 2017; **17**: 570.

**International comparisons**

* Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015; **385**: 977-1010.
* Bonaventure A, Harewood R, Stiller CA, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol* 2017; **4**: e202-e17.
* Breugom A, Bastiaannet E, Boelens P, et al. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer–A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. *European Journal of Cancer* 2016; **63**: 110-7.
* Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. *Eur J Cancer* 2017; **77**: 140-52.
* Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. *Lung cancer (Amsterdam, Netherlands)* 2015; **89**: 212-7.
* de Leede EM, Sibinga Mulder BG, Bastiaannet E, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology* 2016; **42**: 1414-9.
* Fidler MM, Bray F, Vaccarella S, Soerjomataram I. Assessing global transitions in human development and colorectal cancer incidence. *International journal of cancer* 2017; **140**: 2709-15.
* Gatta G, Peris-Bonet R, Visser O, et al. Geographical variability in survival of European children with central nervous system tumours. *Eur J Cancer* 2017; **82**: 137-48.
* Maringe C, Walters S, Rachet B, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000–2007. *Acta Oncologica* 2013; **52**: 919-32.
* Matz M, Coleman MP, Carreira H, et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecologic oncology* 2017; **144**: 396-404.
* Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecologic oncology* 2017; **144**: 405-13.
* Pulte D, Redaniel MT, Lowry L, Bird J, Jeffreys M. Age disparities in survival from lymphoma and myeloma: a comparison between US and England. *British journal of haematology* 2014; **165**: 824-31.
* Rose PW, Rubin G, Perera-Salazar R, et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. *BMJ open* 2015; **5**: e007212.
* Rossi S, Baili P, Capocaccia R, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. *Eur J Cancer* 2015; **51**: 2104-19.
* Sachdeva A, van der Meulen JH, Emberton M, Cathcart PJ. Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA. *BMJ open* 2015; **5**: e006805.
* Sewell J, Ranasinghe W, De Silva D, et al. Trends in penile cancer: a comparative study between Australia, England and Wales, and the US. *SpringerPlus* 2015; **4**: 420.
* Spika D, Bannon F, Bonaventure A, et al. Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods. *BMC Cancer* 2017; **17**: 159.
* Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol* 2017; **18**: 719-31.
* Steliarova-Foucher E, O'Callaghan M, Ferlay J, et al. The European Cancer Observatory: A new data resource. *Eur J Cancer* 2015; **51**: 1131-43.
* Steliarova-Foucher E, Stiller C, Colombet M, Kaatsch P, Zanetti R, Peris-Bonet R. Registration of childhood cancer: Moving towards pan-European coverage? *Eur J Cancer* 2015; **51**: 1064-79.
* Wallingford SC, Iannacone MR, Youlden DR, et al. Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990–2010. *International journal of cancer* 2015; **137**: 2227-33.
* Walters S, Benitez-Majano S, Muller P, et al. Is England closing the international gap in cancer survival? *British journal of cancer* 2015; **113**: 848.
* Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. *International journal of cancer* 2013; **132**: 676-85.
* Walters S, Maringe C, Butler J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *British journal of cancer* 2013; **108**: 1195.
* Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. *Thorax* 2013: thoraxjnl-2012-202297.
* Weller D, Vedsted P, Anandan C, et al. An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. *BMJ open* 2016; **6**: e009641.
* Woods LM, Rachet B, O'connell D, Lawrence G, Coleman MP. Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): Women diagnosed 1997–2006. *International journal of cancer* 2016; **138**: 2396-403.
* Woods LM, Rachet B, O'connell DL, Lawrence G, Coleman MP. Are international differences in breast cancer survival between Australia and the UK present amongst both screen‐detected women and non‐screen‐detected women? survival estimates for women diagnosed in West Midlands and New South Wales 1997–2006. *International journal of cancer* 2016; **138**: 2404-14.
* Luchtenborg M, Morris EJA, Tataru D, et al. Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer. *Thorax* 2018; **73**: 339-49.

**Methodological studies, include risk prediction models and data comparisons**

* Abel G, Saunders CL, Mendonca SC, Gildea C, McPhail S, Lyratzopoulos G. Variation and statistical reliability of publicly reported primary care diagnostic activity indicators for cancer: a cross-sectional ecological study of routine data. *BMJ Qual Saf* 2017.
* Benitez-Majano S, Fowler H, Maringe C, Di Girolamo C, Rachet B. Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England. *British journal of cancer* 2016; **115**: 391.
* Berney DM, Beltran L, Fisher G, et al. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. *British journal of cancer* 2016; **114**: 1078.
* Charvat H, Remontet L, Bossard N, et al. A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates. *Stat Med* 2016; **35**: 3066-84.
* De Stavola BL, Cox D. Detecting bias arising from delayed recording of time. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 2016.
* Eden M, Rous BA, Rashbass J. Misinterpretation of the origins and composition of staging data and its impact on colorectal cancer survival. *Acta Oncol* 2014; **53**: 845-6.
* Gavin A, Rous B, Marcos-Gragera R, et al. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. *Eur J Cancer* 2015; **51**: 1109-22.
* Hippisley-Cox J, Coupland C. Protocol for the development and validation of risk prediction equations to estimate absolute and conditional survival in patients with cancer. 2016.
* Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. *BMJ (Clinical research ed)* 2017; **357**: j2497.
* Mauguen A, Rachet B, Mathoulin-Pélissier S, et al. Validation of death prediction after breast cancer relapses using joint models. *BMC medical research methodology* 2015; **15**: 27.
* Morris EJ, Rutter MD, Finan PJ, Thomas JD, Valori R. Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably depending on the method used to calculate them: a retrospective observational population-based study of PCCRC in the English National Health Service. *Gut* 2015; **64**: 1248-56.
* Roche L, Danieli C, Belot A, et al. Cancer net survival on registry data: use of the new unbiased Pohar‐Perme estimator and magnitude of the bias with the classical methods. *International journal of cancer* 2013; **132**: 2359-69.
* Round C, Mee T, Kirkby N, Cooper T, Williams M, Jena R. The Malthus programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level. *Clinical Oncology* 2013; **25**: 538-45.
* Sanderson B, McWilliam A, Faivre-Finn C, et al. Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer. *Radiotherapy and Oncology* 2017; **122**: 159-62.
* Barclay ME, Lyratzopoulos G, Greenberg DC, Abel GA. Missing data and chance variation in public reporting of cancer stage at diagnosis: Cross-sectional analysis of population-based data in England. *Cancer epidemiology* 2018; **52**: 28-42.
* Burton CD, McLernon DJ, Lee AJ, Murchie P. Distinguishing variation in referral accuracy from referral threshold: analysis of a national dataset of referrals for suspected cancer. *BMJ Open* 2017; **7**: e016439.
* Spencer K, Ellis R, Birch R, et al. Caution is required in the implementation of 90-day mortality indicators for radiotherapy in a curative setting: A retrospective population-based analysis of over 16,000 episodes. *Radiotherapy and Oncology* 2017; **125**: 140-6.
* dos Reis FJC, Wishart GC, Dicks EM, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research* 2017; **19**: 58.
* Merriel SW, May MT, Martin RM. Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. *BMJ open* 2018; **8**: e019409.
* Amjad S, Williams R, Brannan R, Malik T, Valentine J. Creating a Single Application and Approval Process to Enable Research; an example using CPRD Primary Care Data and Public Health England Cancer Registry Data. *International Journal for Population Data Science* 2017; **1**.
* Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. *Pharmacoepidemiol Drug Saf* 2013; **22**: 168-75.
* Perera G, Broadbent M, Callard F, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource. *BMJ Open* 2016; **6**: e008721.
* Di Girolamo C, Walters S, Gildea C, et al. Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009–2013? Implications for use of the data in research. *British journal of cancer* 2018.
* Khakwani A, Jack RH, Vernon S, et al. Apples and pears? A comparison of two sources of national lung cancer audit data in England. *ERJ Open Res* 2017; **3**: 00003-2017.
* Merriel SWD, Turner EL, Walsh E, et al. Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). *BMJ open* 2017; **7**: e015994.
* World Health Organisation. ICD-10: International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva: World Health Organization; 2010.
* Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer* 2005; **103**: 1457-67.
* Birch JM, Alston RD, Kelsey AM, Quinn MJ, Babb P, McNally RJ. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. *Br J Cancer* 2002; **87**: 1267-74.
* Public Health England. *Accessing PHE data through the Office for Data Release*. [cited 26/02/18]; Available from: https://www.gov.uk/government/publications/accessing-public-health-england-data/about-the-phe-odr-and-accessing-data